Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma
- Jiaying Deng†1,
- Chunyu Wang†1,
- Mingqiong Xiang2,
- Fatao Liu3,
- Yun Liu4Email author and
- Kuaile Zhao1Email author
© Deng et al.; licensee BioMed Central Ltd. 2014
Received: 27 May 2014
Accepted: 7 July 2014
Published: 16 July 2014
Many studies have demonstrated that chemoradiotherapy followed by surgery (CRTS) prolongs the 5-year survival rate of resectable esophageal carcinoma patients. However, the effect of CRTS on postoperative complications, local recurrence and distant metastasis remains controversial. We performed a systematic review of the literature and conducted a meta-analysis to assess the postoperative efficacy of CRTS compared with surgery alone (SA).
Pubmed, Web of Science and the Cochrane library Databases were used to identify published studies between 2000 and 2013 that directly compared CRTS with SA. The pooled relative risk (RR) and its corresponding 95% confidence interval (95% CI) constituted the principal measure of treatment effects. Heterogeneity was assessed by the χ2 and I2 statistic.
The final analysis included 1930 resectable esophageal carcinoma cases from 13 randomized controlled trials (RCTs). Compared with SA, CRTS was associated with significantly decreased postoperative mortality, local recurrence and distant metastasis rates, with RR (95% CI) = 0.64 (0.49–0.84), 0.53 (0.39–0.73), 0.82 (0.68–0.98); p = 0.001, <0.00001, =0.03, respectively. However, there was no significant difference in postoperative complication incidence between the two groups (RR, 1.09; 95% CI, 0.96–1.24; p = 0.18).
CRTS significantly decreased postoperative mortality, local recurrence and distant metastasis rates compared to SA. Additionally, there were no increased postoperative complications for patients with resectable esophageal carcinoma.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1531519216130950
KeywordsEsophageal carcinoma Chemoradiotherapy followed by surgery Surgery alone Randomized controlled trial Meta-analysis
Esophageal cancer is a significant health problem worldwide. There are approximately 482,300 new cases of esophageal cancer and 406, 800 deaths annually . Esophagectomy is considered the gold standard treatment for patients with resectable esophageal carcinoma. However, the prognosis for patients treated with surgery alone (SA) remains poor . In addition to advances in supportive care, improved and standardized surgical techniques have also contributed to an increase in the rate of curative resection . Despite changes in management over the past 20 years, SA leads to relatively few long-term survivors . Thus, there is interest in using combinations of chemoradiotherapy and local surgical treatment due to the high rates of locoregional and distant failure. Many studies have investigated the effect of chemoradiotherapy followed by surgery (CRTS) on the postoperative survival rate and quality of life.
There is evidence that neoadjuvant chemoradiotherapy increases the rate of complete resection , particularly for patients with locally advanced disease. Many randomized controlled trials (RCTs) have generated promising results with respect to 5-year survival rates. The evidence supporting the survival benefits of CRTS is clear for both esophageal squamous-cell carcinoma (SCC) and adenocarcinoma (AC) histology compared with SA. Clinicians agree there is a survival advantage associated with the CRTS regimen. However, there are different opinions on the impact of postoperative treatment effects [6, 7]. There is a persistent concern that neoadjuvant treatment may cause an undesirable increase in postoperative complications.
The published meta-analyses have also failed to reach a consensus on postoperative efficacy [8–10]. Therefore, we performed a meta-analysis of prospective RCTs to examine resectable esophageal carcinoma patients treated with CRTS or SA. We compared the postoperative complications, local recurrence and distant metastasis associated with the two treatment regimens. The results of this study provide valuable evidence for clinical decision-making.
Identification of relevant studies
We searched PubMed, Web of Science and the Cochrane library databases to retrieve related studies published between 2000 and 2013. The search terms included “neoadjuvant therapy”, “chemoradiotherapy followed by surgery”, “chemoradiotherapy”, “surgery or operation or esophagectomy”, “esophagus or esophageal cancer or carcinoma”. To Manual searches of reference lists were also performed to ensure that no studies were missed.
The search results met the following inclusion criteria:(1) the study was a prospective RCT designed to compare CRTS with SA treatment of resectable esophageal cancer; (2) the assessment of the liver, kidney, heart, lung, etc. for the included patients have confirmed them to be fit for surgery; (3) the study clearly described the diagnoses and the sources of the cases and controls, the sample size, risk ratio (RR) and their 95% confidence interval (CI), or data that would allow those findings to be inferred; (4) clear follow-up censored survival, complications, number of cases for local recurrence and metastasis, and follow-up rate of > 95% in the original study.
Data extraction and quality assessment
Two investigators (Deng, Wang) independently reviewed titles and abstracts of all citations identified by the literature search. The data were extracted by the one author. Any discrepancies were resolved by discussion among all authors, and consensus was reached. For each study, the following data were extracted: the first author of the study, the year of publication, the author’s country, the treatment regimen, tumor histology, patient outcomes including postoperative mortality, complications, recurrence and distant metastasis.
The trial validity assessment was conducted in dependently and in duplicate. A trial quality score was assigned using three aspects: blinding, randomization and handling of withdrawals and dropouts. These aspects were assessed using a scale of 1–5, according to methods previously described by Jadad et al .
The analysis was performed using Review Manager Version 5.2 software and Stata Version 12.0 software. To combine results from individual trials, we used the proportion of events observed in CRTS and SA groups. The RR with the corresponding 95% CI was calculated for each trial using the observed proportions of events. All patient data were analyzed according to intention-to-treat principles. The overall RR was tested for significance using a Mantel-Haenszel χ2 test. The outcome variables were the treatment RR of the postoperative mortality, complications, local recurrence and distant metastasis rates between CRTS and SA groups. The statistical significance of the summary RR was determined with a Z-test, and p < 0.05 was considered statistically significant. Subgroups of patients were assigned based on ethnicity and histology, and the groups were used to compare the impact on postoperative treatment outcomes.
Evaluation of heterogeneity and publication bias
The heterogeneity assumption was evaluated with a chisquare-based Q-test. A p value ≥ 0.10 for the Q-test indicated a lack of heterogeneity among studies. We used a fixed effects model to calculate the total RR and 95% CI, or used a random effects model. If p < 0.1 and I 2 > 50%, the heterogeneity was regarded as statistically significant. Egger’s test was performed to assess whether there was any publication bias due to the literature evaluated.
Characteristics of eligible studies
Characteristics of 13 RCTs included in the final meta-analysis
Neoadjuvant treatment schedule
SCC (25%); AC (75%)
45 Gy; 1.5 Gy per fraction over 3 weeks
Two cycles: cisplatin 20 mg/m2 days 1–5; fluorouracil 300 mg/m2 days 1–21; vinblastine 1 mg/m2 days 1–4
36 Gy, 1.2 Gy per fraction over 17 days
First cycle: 5-fluorouracil 1 mg/m2, 5–6 hours, days 1–5; cisplatin 25 mg/m2.
Second cycle: 5-fluorouracil 0.5 g/m2, days 21–25; cisplatin 25 mg/m2, days 22–25
45.6 Gy, 1.2 Gy per fraction over 28 day
Two cycles: cisplatin 60 mg/m2 days 1; fluorouracil 1000 mg/m2 days 3–5
SCC (37%); AC (62%)
35 Gy in 15 fractions over 3 weeks
One cycles: cisplatin 80 mg/m2 days 1; fluorouracil 800 mg/m2 days 1–4
40 Gy, 2 Gy per fraction over 4 weeks
cisplatin 7 mg over 2 hours; 5-fluorouracil 350 mg over 24 hours
SCC (25%); AC (75%)
50.4 Gy, 1.8 Gy per fraction over 5.6 weeks
Two cycles: cisplatin 100 mg/m2 days 1; fluorouracil 1000 mg/m2 per day days 1–4
40 Gy, 2 Gy per fraction over 4 weeks
cisplatin 20 mg/m2 per day days 1–5; fluorouracil 500 mg/m2 per day days 1–5; mitomycin 10 mg/m2 per day day 1
SCC (36%); AC (64%)
66 Gy, 2 Gy per fraction over 6.5 weeks
Three cycles: cisplatin 100 mg/m2 days 1; fluorouracil 1000 mg/m2 per day days 1–5
40 Gy, 2 Gy per fraction over 4 weeks
Two cycles: cisplatin 20 mg/m2 per day, days 1–3, 22–25;
paclitaxel 135 mg/m2
30-42 Gy , 1.8 Gy per fraction
cisplatin: 5 mg/m2/day, 5-FU: 250 mg/m2/day, administered on weekdays, repeated every 3-4 weeks
van Hagen 
SCC (23%); AC (75%)
41.4 Gy, 1.8 Gy per fraction over 4.6 weeks
5 weeks chemotherapy: carboplatin area under curve =2 , paclitaxel 50 mg/m2 on day 1 weekly
40 Gy, 2 Gy per fraction over 4 weeks
5-FU (500 mg/m2/day), CDDP (15-20 mg/day), days 1-5, repeated every 3 weeks
41.4 Gy,1.8 Gy per fraction over 4.6 weeks
5 weeks: paclitaxel (50 mg/m2), carboplatin (area under the curve = 2)
Mortality and complications after surgery
Meta-analysis for the outcomes of CRTS versus SA
Test for overall effect
P value for heterogeneity
P value for Egger’s test
RR (95% CI)
0.64 [0.49, 0.84]
1.09 [0.96, 1.24]
0.51 [0.38, 0.70]
0.82 [0.68, 0.98]
Subgroup analysis of the postoperative treatment outcomes
Test for overall effect
RR (95% CI)
Postoperative mortality based on ethnicity
0.83 [0.47, 1.46]
0.56 [0.42, 0.75]
Postoperative complication based on ethnicity
1.00 [0.87, 1.15]
1.23 [0.96, 1.56]
Local recurrence based on ethnicity
0.51 [0.34, 0.76]
0.52 [0.33, 0.84]
Postoperative metastasis based on ethnicity
0.93 [0.75, 1.16]
0.62 [0.44, 0.88]
Postoperative mortality based on histology
0.54 [0.42, 0.68]
1.26 [0.76, 2.06]
A subgroup analysis by histological type for postoperative mortality where histology data were available yielded an RR for SCC of 0.54 (95% CI 0.42–0.68; p < 0.0001), in favor of CRTS. For AC, the RR was 1.26 (0.76–2.06; p = 0.37). There was a significant survival benefit for SCC, but not for AC (Table 3).
Effect on recurrence and metastasis
A subgroup analysis based on ethnicity showed that race had an impact on postoperative local recurrence and distant metastasis for CRTS relative to SA. The RR for postoperative local recurrence was 0.52 (95% CI = 0.33–0.84, p = 0.008) for the East and 0.51 (95% CI = 0.34–0.76, p = 0.001) for the West. The RR for distant metastasis for the East was 0.62 (95% CI = 0.44–0.88, p = 0.007), which was significantly increased by CRTS. However, the RR for the West was 0.93 (95% CI = 0.75–1.16, p = 0.10), which was not significantly increased by CRTS (Table 3).
Sensitivity analysis and publication bias
The sensitivity analysis did not exclude any studies because none of the studies could alter the overall estimates for postoperative mortality, postoperative complications, postoperative local recurrence and postoperative distant metastasis. The Q-test of heterogeneity showed that these analyses had a p ≥0.10 (Table 2), which suggests that neither analyses demonstrated heterogeneity among the included RCTs. We then selected a fixed-effect model and did not introduce a subgroup analysis.
The p values based on Egger’s test for postoperative mortality, complications, local recurrence and distant metastasis are shown in Table 2. The results showed that no publication bias existed for postoperative complications and local recurrence (p = 0.752, 0.386, respectively). However, publication bias existed for postoperative mortality and distant metastasis (p = 0.04, 0.01, respectively). Therefore, these results need to be further examined in additional studies.
Previous studies have demonstrated that CRTS significantly improves the long-term survival rate of esophageal cancer compared with SA alone . Consistent with this result, many RCTs and Meta studies have reached a consensus. We emphasized the investigation of neoadjuvant chemoradiotherapy in the present meta-analysis due to persistent anxiety that neoadjuvant chemoradiotherapy has a negative impact on postoperative treatment effects.
The results of our meta-analysis showed there was a statistically significant advantage for postoperative mortality, local recurrence and distant metastasis of esophageal cancer patients treated with CRTS compared with SA (p < 0.05). This finding is interestingwith respect to a recently updated meta-analysis performed by Sjoquist et al  published in Lancet Oncology. The study included 12 RCTs with 1854 cases and had strict inclusion criteria and rigorous statistical analysis. The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95% CI 0.70-0.88; p < 0.0001). The updated meta-analysis is in accordance with our results and demonstrated the benefit of CRTS in decreasing postoperative mortality compared with SA. The survival benefits for neoadjuvant chemoradiotherapy were similar for squamous-cell carcinoma (HR 0.8, 95% CI 0.68-0.93; p = 0.004) and adenocarcinoma (HR 0.75, 0.59-0.95; p = 0.02) subgroups. The survival benefit for SCC was consistent with our subgroup analysis for SCC (RR 0.54, 95% CI 0.42–0.68; p < 0.0001). There was a smaller benefit associated with AC in our analysis, but it was not statistically significant (RR 1.26, 95% CI 0.76–2.06; p = 0.37).
In a meta-analysis conducted by K. Kumagai1 et al , neoadjuvant chemoradiotherapy patients with SCC were associated with a significantly higher risk of postoperative mortality (RR 1.95, 1.06 - 3.60; p = 0.032) compared with SA. However, there was no difference among patients with AC or in the esophageal cancer group overall. The reason for this finding may be that most of the included trials were conducted in the 1980s. After excluding trials conducted in the 1980s, the results revealed the difference was not statistically significant compared with surgery alone in the SCC subgroup.
Our meta-analysis investigated postoperative local recurrence and distant metastasis. The two indictors were rarely published in previous meta-analyses. Compared with SA, CRTS significantly decreased the local recurrence and distant metastasis rates of the tumor (p < 0.05). This finding may contribute to better survival outcomes and lower postoperative mortality. There was evidence that patients treated with SA were more likely to undergo the scheduled surgery. However, the rate of complete resection in the CRTS group was higher than in the SA group . In theory, neoadjuvant chemoradiotherapy might lead to downstaging of the primary tumor and have positive effects on mediastinal nodes. This may account for the lower local recurrence rate. In this study, no subgroup analysis of postoperative complications, local recurrence or distant metastasis based on histology was investigated because the exact number of patients with these complications was not reported separately for SCC and AC.
We screened 13 RCTs based on different databases from the period of 2000 to 2013 with a larger sample size and a wider distribution range than used in previous studies. This difference is the strength of our study compared to other previous meta-analyses that included studies mostly published in 1990s. The use of radiation has developed rapidly in the past 20 years. Thus, the role of chemoradiotherapy in multimodality therapy has become more important. A systematic analysis using the latest research data is expected to produce more accurate results.
The management of esophageal cancer with neoadjuvant strategies is complex, and the available evidence is conflicting. We have discussed some of these controversies and attempted to resolve them within the context of a well-designed randomized controlled trial. We have made initial recommendations for the trial design, but this remains open for discussion and scrutiny. The meta-analysis in this study has the following limitations: some eligible studies may be missing although our big effort; the current study did lack the accurate number of patients who suffered with postoperative complication, local recurrence and distant metastasis with SCC and AC, respectively. Publication bias existed in postoperative mortality and distant metastasis, which may attribute to less studies included. It seems to us that the conclusions should be interpreted with caution. A larger number studies will be needed to verify our results further.
There is no consensus for the treatment of esophageal carcinoma and standard treatment regimens. However, most clinical studies show that preoperative chemoradiotherapy combined with surgery is a triple therapy model that may improve the clinical efficiency and the long-term survival rate. Thus, this strategy may become the standard treatment regimen . A meta-analysis by Cavallin  revealed that patients with excellent histopathological responses benefit from neoadjuvant regimens. However, patients with poor histopathological responses have no benefit and have worse prognoses. Therefore, predictive markers to allow for individualization of multimodality treatment in locally advanced esophageal cancer are urgently needed. There was evidence that ATP-binding cassette sub-family G member 2 (ABCG2) and Vacuolar-H + -ATPase (V-ATPase) were associated with pathological grade, TNM stage and tumor metastasis in esophageal squamous cancer cells . Furthermore, HER2 overexpression was associated with gastroesophageal junction (GEJ) site, intestinal cancer subtype, and well or moderately differentiated carcinomas . All these markers are associated with clinicopathological features for esophageal carcinoma and contribute to optimize treatment regimen.
CRTS significantly reduced postoperative mortality, local recurrence and distant metastasis rates compared to SA. However, CRTS did not increase the postoperative complication incidence compared with SA.
Chemoradiotherapy followed by surgery
Randomized controlled trials.
This work was financially supported by the National Natural Science Foundation of China Research, China (grant number 21172043).We specially thank Dr. Zhou Zhang from Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, 200030, P.R. China who helped with the analysis software.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.PubMedView Article
- Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009, 27: 5062-5067. 10.1200/JCO.2009.22.2083.PubMedView Article
- Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten KF, Obertop H, Tilanus HW, van Lanschot JJ: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007, 246: 992-1000. 10.1097/SLA.0b013e31815c4037. 1000-1001PubMedView Article
- Khushalani N: Cancer of the esophagus and stomach. Mayo Clin Proc. 2008, 83: 712-722. 10.1016/S0025-6196(11)60900-2.PubMedView Article
- Courrech SE, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW: Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010, 97: 1482-1496. 10.1002/bjs.7175.View Article
- Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011, 29: 1715-1721. 10.1200/JCO.2010.33.0597.PubMedView Article
- Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007, 25: 3719-3725. 10.1200/JCO.2006.10.4760.PubMedView Article
- Greer SE, Goodney PP, Sutton JE, Birkmeyer JD: Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005, 137: 172-177. 10.1016/j.surg.2004.06.033.PubMedView Article
- Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007, 8: 226-234. 10.1016/S1470-2045(07)70039-6.PubMedView Article
- Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-692. 10.1016/S1470-2045(11)70142-5.PubMedView Article
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.PubMedView Article
- Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001, 19: 305-313.PubMed
- An FS, Huang JQ, Xie YT, Chen SH, Rong TH: A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma. Zhonghua Zhong Liu Za Zhi. 2003, 25: 376-379.PubMed
- Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004, 15: 947-954. 10.1093/annonc/mdh219.PubMedView Article
- Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005, 6: 659-668. 10.1016/S1470-2045(05)70288-6. 659-668PubMedView Article
- Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N, Ishigami S, Owaki T, Aikou T: Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006, 19: 468-472. 10.1111/j.1442-2050.2006.00615.x.PubMedView Article
- Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008, 26: 1086-1092. 10.1200/JCO.2007.12.9593.PubMedView Article
- Cao XF, He XT, Ji L, Xiao J, Lv J: Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 2009, 22: 477-481. 10.1111/j.1442-2050.2008.00910.x.PubMedView Article
- Hurmuzlu M, Ovrebo K, Monge OR, Smaaland R, Wentzel-Larsen T, Viste A: High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. World J Surg Oncol. 2010, 8: 46-10.1186/1477-7819-8-46.PubMedPubMed CentralView Article
- Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD: Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol. 2010, 16: 1649-1654. 10.3748/wjg.v16.i13.1649.PubMedPubMed CentralView Article
- van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge HM, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012, 366: 2074-2084. 10.1056/NEJMoa1112088.PubMedView Article
- Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Hara J, Yamamura T, Inoue M: Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Mol Clin Oncol. 2013, 1: 773-779.PubMedPubMed Central
- Smit JK, Guler S, Beukema JC, Mul VE, Burgerhof JG, Hospers GA, Plukker JT: Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. Ann Surg Oncol. 2013, 20: 4008-4015. 10.1245/s10434-013-3102-7.PubMedView Article
- Saeki H, Morita M, Nakashima Y, Sonoda H, Hashimoto K, Egashira A, Oki E, Ohga T, Kakeji Y, Maehara Y: Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. Anticancer Res. 2011, 31: 3073-3077.PubMed
- Kelly P, Appleyard V, Murray K, Paulin F, Lamont D, Baker L, Suttie S, Exon D, Thompson A: Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer. 2010, 103: 232-238. 10.1038/sj.bjc.6605741.PubMedPubMed CentralView Article
- Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Klevebro F, Lindblad M, Ye W, Lundell L, Nilsson M: Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014, 101: 321-338. 10.1002/bjs.9418.PubMedView Article
- Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH: Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol. 2009, 15: 5983-5991. 10.3748/wjg.15.5983.PubMedPubMed CentralView Article
- Zemanova M, Novak F, Vitek P, Pazdro A, Smejkal M, Pazdrova G, Petruzelka L: Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors. J BUON. 2012, 17: 310-316.PubMed
- Cavallin F, Scarpa M, Alfieri R, Cagol M, Castoro C: The Role of Surgery in Patients With a Complete Clinical Response After Chemoradiation for Esophageal Cancer. Ann Surg. 2014, doi:10.1097/SLA.0000000000000666
- Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X: ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 2012, 7: 180-10.1186/1746-1596-7-180.PubMedPubMed CentralView Article
- Shan L, Ying J, Lu N: HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013, 8: 76-10.1186/1746-1596-8-76.PubMedPubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.